MedTrace Logo

Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects

NCT01520987 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 105

Last updated 2016-06-20

Study results available
· View outcomes & findings →

Summary

To assess the pharmacokinetics of BIA 9-1067 in healthy Japanese subjects

Conditions

  • Parkinson Disease

Interventions

DRUG

BIA 9-1067

5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).

DRUG

Placebo

once-daily

Sponsors & Collaborators

  • Bial - Portela C S.A.

    lead INDUSTRY

Principal Investigators

  • Haejung Marr, MD · Covance

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01520987 on ClinicalTrials.gov